Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$4.55 - $6.31 $227,500 - $315,500
50,000 New
50,000 $248,000
Q1 2022

May 16, 2022

SELL
$4.26 - $7.48 $1.06 Million - $1.86 Million
-249,283 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$4.75 - $7.5 $445,383 - $703,237
-93,765 Reduced 27.33%
249,283 $1.85 Million
Q3 2021

Nov 15, 2021

SELL
$5.02 - $6.59 $1.74 Million - $2.28 Million
-346,001 Reduced 50.21%
343,048 $1.95 Million
Q2 2021

Aug 16, 2021

SELL
$5.79 - $8.6 $666,677 - $990,229
-115,143 Reduced 14.32%
689,049 $4.54 Million
Q1 2021

May 12, 2021

BUY
$6.5 - $10.53 $1.23 Million - $1.99 Million
188,906 Added 30.7%
804,192 $6.51 Million
Q4 2020

Feb 16, 2021

BUY
$3.7 - $7.66 $2.28 Million - $4.71 Million
615,286 New
615,286 $3.97 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Pura Vida Investments, LLC Portfolio

Follow Pura Vida Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pura Vida Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pura Vida Investments, LLC with notifications on news.